Author:
Reni M.,Cereda S.,Bonetto E.,Viganò M. G.,Passoni P.,Zerbi A.,Balzano G.,Nicoletti R.,Staudacher C.,Di Carlo V.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference34 articles.
1. Moore MJ, Goldstein D, Hamm J et al (2005) Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trial Group (NCIC-CTG). In: Proceedings of the 2005 Gastrointestinal Cancers Symposium, Hollywood, FL, USA, 3: abstr 77, 27–29 Jan 2005
2. Cunningham D, Chau I, Stocken D et al (2005) Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Eur J Cancer 3:12 (abstr PS 11)
3. Reni M, Cordio S, Milandri C et al (2005) Gemcitabine versus cisplatin, epirubicin, 5-fluorouracil, gemcitabine in advanced pancreatic cancer: a phase III trial. Lancet Oncol 6:369–376
4. Reni M, Passoni P, Panucci MG et al (2001) Definitive results of a phase II trial of PEF-G (cisplatin, epirubicin, 5-fluorouracil continuous infusion, gemcitabine) in stage IV pancreatic adenocarcinoma. J Clin Oncol 19:2679–2686
5. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al (1997) Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献